- Home
- JELD vs ARVN Comparison
JELD vs ARVN Comparison
Compare JELD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JELD
- ARVN
- Stock Information
- Founded
- JELD 1960
- ARVN 2015
- Country
- JELD United States
- ARVN United States
- Employees
- JELD N/A
- ARVN N/A
- Industry
- JELD Forest Products
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- JELD Basic Materials
- ARVN Health Care
- Exchange
- JELD Nasdaq
- ARVN Nasdaq
- Market Cap
- JELD 540.5M
- ARVN 438.1M
- IPO Year
- JELD 2017
- ARVN 2018
- Fundamental
- Price
- JELD $5.16
- ARVN $8.60
- Analyst Decision
- JELD Hold
- ARVN Buy
- Analyst Count
- JELD 8
- ARVN 15
- Target Price
- JELD $8.94
- ARVN $31.86
- AVG Volume (30 Days)
- JELD 1.6M
- ARVN 2.8M
- Earning Date
- JELD 05-05-2025
- ARVN 05-06-2025
- Dividend Yield
- JELD N/A
- ARVN N/A
- EPS Growth
- JELD N/A
- ARVN N/A
- EPS
- JELD N/A
- ARVN N/A
- Revenue
- JELD $3,775,592,000.00
- ARVN $263,399,999.00
- Revenue This Year
- JELD N/A
- ARVN N/A
- Revenue Next Year
- JELD $4.05
- ARVN N/A
- P/E Ratio
- JELD N/A
- ARVN N/A
- Revenue Growth
- JELD N/A
- ARVN 235.54
- 52 Week Low
- JELD $4.91
- ARVN $5.94
- 52 Week High
- JELD $21.75
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- JELD 35.83
- ARVN 48.35
- Support Level
- JELD $5.01
- ARVN $5.94
- Resistance Level
- JELD $5.37
- ARVN $6.86
- Average True Range (ATR)
- JELD 0.39
- ARVN 0.57
- MACD
- JELD -0.02
- ARVN 0.51
- Stochastic Oscillator
- JELD 19.14
- ARVN 98.51
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.